With the global cancer burden growing, is a universal germline genomic testing approach the key to more effectively combating the disease?
The current landscape of molecular hematopathology—and what steps clinical labs can take to stay at the forefront of the discipline
The latest developments in liquid biopsy and ctDNA testing and why they should be of interest to clinical laboratory professionals
What lab tests currently inform mental health care—and how might the testing landscape change as our understanding and technologies evolve?
Andreas Jeromin, PhD, chief scientific officer at ALZPath, discusses the current landscape of blood-based AD tests and their future.